argenx SE
XBRU:ARGX
Relative Value
The Relative Value of one
ARGX
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 630.6 EUR,
argenx SE
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ARGX Competitors Multiples
argenx SE Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
argenx SE
XBRU:ARGX
|
39.2B EUR | 11 | 35.2 | 38.3 | 39.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402B USD | 6.6 | 96.6 | 15.8 | 22 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.9B USD | 5.5 | 26.3 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD | 6.2 | 21.6 | 13.4 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.7B USD | 10.4 | 31.7 | 24 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.2B USD | 11.4 | 134.5 | 75 | 83.3 |